The role of TP53 in cervical carcinogenesis

Human Mutation

Volumn 21, Issue 3, 2003, Pages 307-312

  Tommasino, Massimo ^a   Accardi, Rosita ^b   Caldeira, Sandra ^b   Dong, Wen ^b   Malanchi, Ilaria ^b   Smet, Anouk ^b   Zehbe, Ingeborg ^b  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NONE

Author keywords

Cancer; Cervical cancer; E6 mediated p53 inactivation; E6AP; HPV; Human papilloma virus; p53; TP53; Tumor; UBE3A

Indexed keywords

ONCOPROTEIN; PROTEIN P53; UBIQUITIN PROTEIN LIGASE; UBIQUITIN PROTEIN LIGASE E3A; UNCLASSIFIED DRUG;

CANCER RISK; CARCINOGENESIS; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; REVIEW; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; WART VIRUS;

FEMALE; HUMANS; MUTATION; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS;

EID: 0037217686     PISSN: 10597794     EISSN: None     Source Type: Journal    
DOI: 10.1002/humu.10178     Document Type: Review

References (54)

1. Agorastos T, Lambropoulos AF, Constantinidis TC, Kotsis A, Bontis JN. 2000. p53 codon 72 polymorphism and risk of intra-epithelial and invasive cervical neoplasia in Greek women. Eur J Cancer Prev 9:113-118.
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. 1995. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments]. J Natl Cancer Inst 87:796-802.
3. Busby-Earle RMC, Steel CM, Williams ARW, Cohen B, Bird CC. 1994. p53 mutations in cervical carcinogenesis-low frequency and lack of correlation with human papillomavirus status. Br J Cancer 69:732-737.
4. Butz K, Denk C, Ullmann A, Scheffner M, Hoppe-Seyler F. 2000. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. Proc Natl Acad Sci USA 97:6693-6697.
5. Crook T, Wrede D, Vousden KH. 1991. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 6:873-875.
6. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. 1992. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumors. Lancet 339:1070-1073.
7. Denk C, Butz K, Schneider A, Durst M, Hoppe-Seyler F. 2001. p53 mutations are rare events in recurrent cervical cancer. J Mol Med 79:283-288.
8. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. 1992. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 52:5323-5328.
9. Helland A, Holm R, Kristensen G, Kaern J, Karlsen F, Trope C, Nesland JM, Borresen AL. 1993. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas. J Pathol 171:105-114.
10. Helland A, Langerod A, Johnsen H, Olsen AO, Skovlund E, Borresen-Dale AL. 1998. p53 polymorphism and risk of cervical cancer [letter; comment]. Nature 396:530-531, discussion 532.
11. Hildesheim A, Schiffman M, Brinton LA, Fraumeni JF Jr, Herrero R, Bratti MC, Schwartz P, Mortel R, Barnes W, Greenberg M, McGowan L, Scott DR, Martin M, Herrera JE, Carrington M. 1998. p53 polymorphism and risk of cervical cancer [letter; comment]. Nature 396:531-532.
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC. 1991. p53 mutations in human cancers. Science 253:49-53.
13. Huibregtse JM, Scheffner M, Howley PM. 1991. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 10: 4129-4136.
14. Iwasaka T, Oh-uchida M, Matsuo N, Yokoyama M, Fukuda K, Hara K, Fukuyama K, Hori K, Sugimori H. 1993. Correlation between HPV positivity and state of the p53 gene in cervical carcinoma cell lines. Gynecol Oncol 48:104-109.
15. Jones CJ, Brinton LA, Hamman RF, Stolley PD, Lehman HF, Levine RS, Mallin K. 1990. Risk factors for in situ cervical cancer: results from a case-control study. Cancer Res 50:3657-3662.
16. Josefsson AM, Magnusson PK, Ylitalo N, Quarforth-Tubbin P, Ponten J, Adami HO, Gyllensten UB. 1998. p53 polymorphism and risk of cervical cancer [letter; comment]. Nature 396:531, discussion 532.
17. Kim HJ, Song ES, Hwang TS. 2001. Higher incidence of p53 mutation in cervical carcinomas with intermediate-risk HPV infection. Eur J Obstet Gynecol Reprod Biol 98: 213-218.
18. Kim JW, Cho YH, Lee CG, Kim JH, Kim HK, Kim EJ, Han KT, Namkoong, SE. 1997. Human papillomavirus infection and TP53 gene mutation in primary cervical carcinoma. Acta Oncol 36:295-300.
19. Lanham S, Campbell I, Watt P, Gornall R. 1998. p53 polymorphism and risk of cervical cancer [letter; comment]. Lancet 352:1631.
20. Lechner MS, Laimins LA. 1994. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 68:4262-4273.
21. Li X, Coffino P. 1996. High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. J Virol 70:4509-4516.
22. Magnusson PK, Sparen P, Gyllensten UB. 1999. Genetic link to cervical tumors. Nature 400:29-30.
23. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, Storey A, Matlashewski G. 2000. P53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 87:528-533.
24. Mantovani F, Banks L. 2001. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene 20:7874-7887.
25. Marin MC, Jost CA, Irwin MS, DeCaprio JA, Caput D, Kaelin WG Jr. 1998. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol Cell Biol 18:6316-6324.
26. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T. 1995. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 63:639-645.
27. Minaguchi T, Kanamori Y, Matsushima M, Yoshikawa H, Taketani Y, Nakamura Y. 1998. No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Res 58:4585-4586.
28. Moll UM, Erster S, Zaika A. 2001. p53, p63 and p73-solos, alliances and feuds among family members. Biochim Biophys Acta 1552:47-59.
29. Moreno V, Munoz N, Bosch FX, de Sanjose S, Gonzalez LC, Tafur L, Gili M, Izarzugaza I, Navarro C, Vergara A, Viladiu P, Ascunce N, Shah KV. 1995. Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 4:459-467.
30. Moreno V, Bosch FX, Munoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S. 2002. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 359:1085-1092.
31. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah KV, Meijer CJ, Bosch FX. 2002. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 359: 1093-1101.
32. Nakagawa S, Yoshikawa H, Jimbo H, Onda T, Yasugi T, Matsumoto K, Kino N, Kawana K, Kozuka T, Nakagawa K, Aoki M, Taketani Y. 1999. Elderly Japanese women with cervical carcinoma show higher proportions of both intermediate-risk human papillomavirus types and p53 mutations. Br J Cancer 79:1139-1144.
33. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainau P. 2002. IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 19:607-614.
34. Ostor AG. 1993. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 12:186-192.
35. Park DJ, Wilczynski SP, Paquette RL, Miller CW, Koeffler HP. 1994. p53 mutations in HPV-negative cervical carcinoma. Oncogene 9:205-210.
36. Park JS, Kim EJ, Lee JY, Sin HS, Namkoong SE, Um SJ. 2001. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int J Cancer 91:822-827.
37. Patel D, Huang SM, Baglia LA, McCance DJ. 1999. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. Embo J 18: 5061-5072.
38. Pisani P, Bray F, Parkin DM. 2002. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97:72-81.
39. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-1136.
40. Scheffner M, Munger K, Byrne JC, Howley PM. 1991. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc Natl Acad Sci USA 88: 5523-5527.
41. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. 1993. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75:495-505.
42. Schiffman MH, Haley NJ, Felton JS, Andrews AW, Kaslow RA, Lancaster WD, Kurman RJ, Brinton LA, Lannom LB, Hoffmann D. 1987. Biochemical epidemiology of cervical neoplasia: measuring cigarette smoke constituents in the cervix. Cancer Res 47:3886-3888.
43. Srivastava S, Tong YA, Devadas K, Zou ZQ, Chen Y, Pirollo KF, Chang EH. 1992. The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell lines. Carcinogenesis 13:1273-1275.
44. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L. 1998. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer [see comments]. Nature 393:229-234.
45. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. 1999a. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092-1100.
46. Thomas M, Pim D, Banks L. 1999b. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18:7690-7700.
47. Tommasino M. 2001. Early genes of human papillomaviruses. Encyclopedic reference of cancer. Springer-Verlag p. 266-272.
48. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189:12-19.
49. Yaginuma Y, Westphal H. 1991. Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 51:6506-6509.
50. Zehbe I, Tommasino M. 1999. The biological significance of human papillomavirus type 16 variants for the development of cervical neoplasia. Papillomavirus Report 10:105-116.
51. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. 1999. Codon 72 polymorphism of p53 and its association with cervical cancer [letter]. Lancet 354:218-219.
52. Zehbe I, Voglino G, Wilander E, Delius H, Marongiu A, Edler L, Klimek F, Andersson S, Tommasino M. 2001. p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Res 61:608-611.
53. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ. 1999. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol 73:6209-6219.
54. zur Hausen H. 2002. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342-350.